Management of autoimmune neuropathies has remained unchanged for much of the past 30 years, but recent advances are changing the rate of progress. In this Review, the authors summarize the latest developments, including discoveries in disease mechanisms, new diagnostic guidelines, identification of new biomarkers and the status of promising clinical trials.
FLASH radiotherapy delivers a cancer treatment dose in less than a second, reducing side effects while maintaining tumour control. This Review explores technological advances, safety considerations and future directions needed to bring this promising ultra-fast radiotherapy approach into clinical practice.
The team wanted to understand how immune cells of the brain, called microglia, contribute to Alzheimer’s disease (AD) pathology. It’s known that subtle changes, or mutations, in genes expressed in microglia are associated with an increased risk for developing late-onset AD.
The study focused on one such mutation in the microglial gene TREM2, an essential switch that activates microglia to clean up toxic amyloid plaques (abnormal protein deposits) that build up between nerve cells in the brain. This mutation, called T96K, is a “gain-of-function” mutation in TREM2, meaning it increases TREM2 activation and allows the gene to remain super active.
They explored how this mutation impacts microglial function to increase risk for AD. The authors generated a mutant mouse model carrying the mutation, which was bred with a mouse model of AD to have brain changes consistent with AD. They found that in female AD mice exclusively, the mutation strongly reduced the capability of microglia to respond to toxic amyloid plaques, making these cells less protective against brain aging.
Researchers at the University of Massachusetts Amherst have shown that their nanoparticle-based vaccine can successfully prevent several aggressive cancers in mice, including melanoma, pancreatic cancer, and triple-negative breast cancer. Depending on the cancer type, up to 88% of vaccinated mice stayed tumor-free (depending on the cancer), and the vaccine also reduced — and in some cases completely prevented — the spread of cancer throughout the body.
“By engineering these nanoparticles to activate the immune system via multi-pathway activation that combines with cancer-specific antigens, we can prevent tumor growth with remarkable survival rates,” says Prabhani Atukorale, assistant professor of biomedical engineering in the Riccio College of Engineering at UMass Amherst and corresponding author on the paper.
Atukorale had previously shown that her nanoparticle-based drug design could shrink or eliminate tumors in mice. The new findings reveal that this approach can also prevent cancer from forming in the first place.
Memory loss may not simply be a symptom of getting older. New research from Virginia Tech shows that it’s tied to specific molecular changes in the brain and that adjusting those processes can improve memory.
In two complementary studies, Timothy Jarome, associate professor in the College of Agriculture and Life Sciences’ School of Animal Sciences, and his graduate students used gene-editing tools to target those age-related changes to improve memory performance in older subjects. The work was conducted on rats, a standard model for studying how memory changes with age.
“Memory loss affects more than a third of people over 70, and it’s a major risk factor for Alzheimer’s disease,” said Jarome, who also holds an appointment in the School of Neuroscience. “This work shows that memory decline is linked to specific molecular changes that can be targeted and studied. If we can understand what’s driving it at the molecular level, we can start to understand what goes wrong in dementia and eventually use that knowledge to guide new approaches to treatment.”
Many young ADHD patients are medicated as soon as they’re diagnosed, possibly because the behavioral therapy they need isn’t available, a Stanford Medicine-led study found.
